ReviewJournal for immunotherapy of cancer2020
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Hanne Lind et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
177 papers cite itlatest 60 shown
this paperpooled ittrialcites it